Education
About Us
Working with TipRanks
Follow Us
Valneva (VALN)
NASDAQ:VALN
VALN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.62 - $9.50
Previous CloseN/A
Volume18.63K
Average Volume (3M)43.71K
Market Cap
$588.03M
Enterprise Value$539.83M
Total Cash (Recent Filing)€254.49M
Total Debt (Recent Filing)€152.73M
Price to Earnings (P/E)―
Beta0.32
Next Earnings
May 07, 2025EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding81,260,765
10 Day Avg. Volume18,988
30 Day Avg. Volume43,708
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)10.89
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$16.00Price Target Upside123.46% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Valneva News
PremiumCompany Announcements
Valneva SE Reports Strong 2024 Financial Performance---
Bulls Say, Bears Say
Bulls Say
Market ExpansionIxchiq received an extension to the EU label to include active immunization of children from 12 years of age, expanding its potential market.
Sales PerformanceIxchiq sales exceeded estimates, with initial sales of €3.7M, highlighting strong market performance.
Vaccine ApprovalThe FDA granted Ixchiq accelerated approval for the prevention of disease caused by the chikungunya virus.
Bears Say
Financial GuidanceValneva is lowering its 2025 revenue and EPS estimates, indicating challenges in meeting previous expectations.
Operational RisksRisks include commercial, regulatory, development, manufacturing, financial/dilution, and liability.
---
Ownership Overview
―
Insiders
0.15%
Mutual Funds
0.49% Other Institutional Investors
99.36% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
VALN FAQ
What was Valneva’s price range in the past 12 months?
Valneva lowest stock price was $3.62 and its highest was $9.50 in the past 12 months.
What is Valneva’s market cap?
Valneva’s market cap is $588.03M.
When is Valneva’s upcoming earnings report date?
Valneva’s upcoming earnings report date is May 07, 2025 which is in 40 days.
How were Valneva’s earnings last quarter?
Valneva released its earnings results on Mar 20, 2025. The company reported -$0.366 earnings per share for the quarter, missing the consensus estimate of -$0.187 by -$0.179.
Is Valneva overvalued?
According to Wall Street analysts Valneva’s price is currently Undervalued.
Does Valneva pay dividends?
Valneva does not currently pay dividends.
What is Valneva’s EPS estimate?
Valneva’s EPS estimate is -0.28.
How many shares outstanding does Valneva have?
Valneva has 81,260,765 shares outstanding.
What happened to Valneva’s price movement after its last earnings report?
Valneva reported an EPS of -$0.366 in its last earnings report, missing expectations of -$0.187. Following the earnings report the stock price went up 7.727%.
Which hedge fund is a major shareholder of Valneva?
Currently, no hedge funds are holding shares in VALN
---
Valneva Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$16.00 (123.46% Upside)
$16.00 (123.46% Upside)
Blogger Sentiment
Bullish
VALN Sentiment 100%
Sector Average 69%
Sector Average 69%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 13.4%
Last 30 Days ▼ 13.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-8.86%
12-Months-Change
Fundamentals
Return on Equity
-7.59%
Trailing 12-Months
Asset Growth
1.81%
Trailing 12-Months
Company Description
Valneva
Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2. The company also develops VLA15, a vaccine candidate that has completed Phase II clinical trial against Borrelia; and VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is headquartered in Saint-Herblain, France.
---
VALN Company Deck
---
VALN Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Valneva had a successful year with achieved sales growth, a solid cash position, and strong regulatory and R&D progress. However, challenges such as delayed approvals and slower than expected market dynamics for IXCHIQ contribute to a balanced outlook.Read More>---
VALN Stock 12 Month Forecast
Average Price Target
$16.00
▲(123.46% Upside)
Technical Analysis
Best Analysts Covering VALN
1 Year
1 Year Success Rate
5/25 ratings generated profit
1 Year Average Return
-16.32%
reiterated a buy rating 4 days ago
Copying Edward White's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of -16.32% per trade.
---